pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›SEVELAMER CARBONATE
drug
save

SEVELAMER CARBONATE

Marketedupdated 3mo ago
by TWi Pharmaceuticals USA Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 4
  • tagApproval2 co-mentions · 1 sources
  • companyNavinta LLC1 co-mentions · 1 sources
  • tagSmall Molecule1 co-mentions · 1 sources
  • drugRenvela1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying SEVELAMER CARBONATE

  • phase3AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemiacompletedn=474
  • phase3FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Diseasecompletedn=98
  • phase2Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemiarecruitingn=50
  • phase4Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binderscompletedn=44
  • phase3Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysiscompletedn=239
  • phase2A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patientscompletedn=55
  • phase3A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysiscompletedn=1,559

News(0)

no news has mentioned this drug yet

brand
SEVELAMER CARBONATE
generic
SEVELAMER CARBONATE
indication
Hyperphosphatemia In Chronic Kidney Disease
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 14m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?